Medical Advocates
Darunavir (Prezista/TMC-114)
  Main Page

New and Noteworthy
FDA Updates
 Product Information
Protease Inhibitors: General Data
 Journal Data
 Conference Data
Pediatric Data
Perinatal  Data


 		  
ARV Drugs Main Page Drugs Main Page Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  October 07, 2008 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
October 2008
 
September 2008
 
FDA Updates
     
Product Information
     
Pediatric Data
     
USPHS Pediatric Antiretroviral Drug Information
US Treatment Guidelines
    
Conference Reports, Abstracts and Posters
 
 
Safety and Efficacy of Darunavir Co-administered with Low-dose Ritonavir in Treatment-experienced
Children and Adolescents at Week 24
 R Bologna, S Rugina, P Cahn, et al
 (15th CROI)
Abstract
 
Dose selection of darunavir co-administered with low-dose ritonavir (DRV/r) in
treatment-experienced HIV-1-infected children and adolescents
 Spinosa-Guzman S, Sekar VJ, Van Baelen B, et al
 (4th IAS Conference)
Abstract

Salvage therapy in perinatally acquired HIV infection: first UK experience of TMC114
 A Bamford, C Foster, NE Mackie, et al|
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
Perinatal Data
       
Guidelines
 
     United States

          Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines

ARV Drugs Main Page Drugs Main Page Home Page      

Darunavir (Prezista/TMC114)